Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.Across the 68 markets, sales ...

A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control, and adding savory flavors are ways that ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...